Pernix Therapeutical Holdings Overview
- Year Founded
-
1996
- Status
-
Private
- Employees
-
147
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
13
- Investments
-
12
Pernix Therapeutical Holdings General Information
Description
Developer and marketer of specialty pharmaceutical products intended to expand access to clinically differentiated, underappreciated medicines as both branded and generic. The company focuses on the acquisition, development, and commercialization of prescription drugs and aims to underserved therapeutic areas, such as the central nervous system, including neurology, pain and psychiatry.
Contact Information
Website
www.pernixtx.comCorporate Office
- 155 Franklin Road
- Suite 450
- Brentwood, TN 37027
- United States
Corporate Office
- 155 Franklin Road
- Suite 450
- Brentwood, TN 37027
- United States
Pernix Therapeutical Holdings Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Pernix Therapeutical Holdings Comparisons
Industry
Financing
Details
Pernix Therapeutical Holdings Competitors (42)
One of Pernix Therapeutical Holdings’s 42 competitors is Novartis, a Corporation company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novartis | Corporation | Basel, Switzerland | ||||
| Cipla | Corporation | Mumbai, India | ||||
| Landsteiner Scientific | Formerly PE-Backed | Toluca, Mexico | ||||
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| Chiesi Farmaceutici | Private Debt Financed | Parma, Italy |
Pernix Therapeutical Holdings Patents
Pernix Therapeutical Holdings Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10150784-B2 | Crystal polymorph of magnesium glycinate dihydrate and process for its preparation | Inactive | 30-Nov-2012 | ||
| US-20140186408-A1 | Crystal polymorph of magnesium glycinate dihydrate and process for its preparation | Active | 30-Nov-2012 | ||
| US-20160326188-A1 | Crystal polymorph of magnesium glycinate dihydrate and process for its preparation | Active | 30-Nov-2012 | ||
| US-9394318-B2 | Crystal polymorph of magnesium glycinate dihydrate and process for its preparation | Inactive | 30-Nov-2012 | ||
| US-20110045063-A2 | Phosphate-binding magnesium salts and uses thereof | Active | 10-Apr-2009 | A61K33/06 |
Pernix Therapeutical Holdings Signals
Pernix Therapeutical Holdings Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Pernix Therapeutical Holdings Investments & Acquisitions (12)
Pernix Therapeutical Holdings’s most recent deal was a Merger/Acquisition with Nalpropion Pharmaceuticals. The deal was made on 27-Sep-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Nalpropion Pharmaceuticals | 27-Sep-2019 | Merger/Acquisition | Pharmaceuticals | ||
| North American Right to ONZETRA XSAIL | 26-Sep-2019 | Corporate Asset Purchase | Buildings and Property | ||
| Zogenix (Zohydro business) | 24-Apr-2015 | Merger/Acquisition | Pharmaceuticals | ||
| GlaxoSmithKline (Treximet sumatriptan / naproxen sodium) | 20-Aug-2014 | Merger/Acquisition | Drug Discovery | ||
| KHEDEZLA | 27-Feb-2014 | Corporate Asset Purchase | Buildings and Property |
Pernix Therapeutical Holdings Exits (1)
Pernix Therapeutical Holdings’s most recent exit was on 02-Jul-2012 from Pernix Manufacturing. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Pernix Manufacturing | 02-Jul-2012 | Completed |
|
Pernix Therapeutical Holdings FAQs
-
When was Pernix Therapeutical Holdings founded?
Pernix Therapeutical Holdings was founded in 1996.
-
Where is Pernix Therapeutical Holdings headquartered?
Pernix Therapeutical Holdings is headquartered in Brentwood, TN.
-
What is the size of Pernix Therapeutical Holdings?
Pernix Therapeutical Holdings has 147 total employees.
-
What industry is Pernix Therapeutical Holdings in?
Pernix Therapeutical Holdings’s primary industry is Drug Discovery.
-
Is Pernix Therapeutical Holdings a private or public company?
Pernix Therapeutical Holdings is a Private company.
-
What is Pernix Therapeutical Holdings’s current revenue?
The current revenue for Pernix Therapeutical Holdings is .
-
How much funding has Pernix Therapeutical Holdings raised over time?
Pernix Therapeutical Holdings has raised $216M.
-
Who are Pernix Therapeutical Holdings’s investors?
Highbridge Capital Management has invested in Pernix Therapeutical Holdings.
-
Who are Pernix Therapeutical Holdings’s competitors?
Novartis, Cipla, Landsteiner Scientific, Astellas Pharma, and Chiesi Farmaceutici are some of the 42 competitors of Pernix Therapeutical Holdings.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process